CN112592344B - Indolo [2,3-b ] indole derivative and synthetic method thereof - Google Patents

Indolo [2,3-b ] indole derivative and synthetic method thereof Download PDF

Info

Publication number
CN112592344B
CN112592344B CN202011293410.1A CN202011293410A CN112592344B CN 112592344 B CN112592344 B CN 112592344B CN 202011293410 A CN202011293410 A CN 202011293410A CN 112592344 B CN112592344 B CN 112592344B
Authority
CN
China
Prior art keywords
indole
cyclohexanone
group
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011293410.1A
Other languages
Chinese (zh)
Other versions
CN112592344A (en
Inventor
邓国军
姜平宇
陈善平
黄华文
肖福红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiangtan University
Original Assignee
Xiangtan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiangtan University filed Critical Xiangtan University
Priority to CN202011293410.1A priority Critical patent/CN112592344B/en
Publication of CN112592344A publication Critical patent/CN112592344A/en
Application granted granted Critical
Publication of CN112592344B publication Critical patent/CN112592344B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

The invention mainly relates to an indolo [2,3-b ] indole and a derivative thereof and a synthesis method thereof, wherein a technical scheme that a 2- (3-indolyl) cyclohexanone compound and an aniline compound are converted into a polysubstituted indolo [2,3-b ] indole derivative only under the action of an iodine reagent and an organic solvent without using a metal catalyst during synthesis is provided; the method solves the problems that the existing synthesis method of the functionalized indolo [2,3-b ] indole compound has complex synthesis steps, can be completed by adopting a multi-step synthesis process, and also needs a metal catalyst or peroxide and raw materials are difficult to prepare; it maintains atom economy to the utmost extent; the method also has the characteristics of simple reaction system, mild reaction conditions, less reaction equipment, simple and convenient experimental operation, wide material sources, high yield, easy expansion of users and applications, higher product utilization value, predictable market commercialization prospect and the like.

Description

Indolo [2,3-b ] indole derivative and synthetic method thereof
Technical Field
The invention relates to an indolo [2,3 ]-b]Indole derivatives and a synthetic method thereof, belonging to the technical field of organic synthesis.
Background
The indoindole is an important skeleton structure of a plurality of medicines, medicine intermediates, organic electrochemical devices and organic luminescent materials, and is widely applied to the fields of organic luminescent semiconductors, medicines and photoelectric materials. Therefore, methods for synthesizing indolo-indole derivatives have been gaining wide attention. The existing method for synthesizing the compounds has the defects that the synthesis steps are complex, a multi-step synthesis process is needed for completion, a transition metal catalyst and a metal oxidant with chemical equivalent are needed to be added, and a starting raw material with relatively high activity is needed to be used.
Disclosure of Invention
In view of the above, it is an object of the present invention to provide an indolo [2,3 ]-b]Indole and derivatives thereof, which have stable molecular structure and excellent chemical properties, are important molecular blocks, are compound fragments containing physiological activity and pharmacological activity, have certain photoelectric properties and generate electricityPhysical activity and pharmaceutical activity.
It is still another object of the present invention to provide an indolo [2,3 ]-b]The method for preparing indole, the derivative and the derivative has the advantages of scientific and reasonable process, easy operation, few reaction steps, simple required equipment, cheap and easily-obtained raw materials, no need of using a metal catalyst and a metal oxidant in the reaction, capability of keeping atom economy to a large extent in the reaction, low input and high output, and easiness in industrial production and popularization.
To achieve the above object, indolo [2,3 ]-b]Indoles and derivatives thereof having the general formula:
Figure 458052DEST_PATH_IMAGE001
Ⅰ
wherein
R1Selected from hydrogen atoms; a linear, branched alkyl group of C1-C10; a benzyl group; a substituted or unsubstituted C6-C20 aryl group;
R2selected from hydrogen atoms; a linear, branched alkyl group of C1-C10; halogen; an alkoxy group; an ester group;
R3selected from hydrogen atoms; a linear chain of C1-C10;
R4selected from hydrogen atoms; a linear, branched alkyl group of C1-C10; halogen; an alkoxy group; an ester group; a nitro group; a cyano group; a trifluoromethyl group; a trifluoromethoxy group; acetyl; substituted or unsubstituted C6-C14 aryl.
The invention also provides an indolo [2,3 ]-b]The method for preparing indole derivatives is characterized in that a catalyst, an oxidant, aniline compounds, 2- (3-indolyl) cyclohexanone and derivatives thereof and an organic solvent are mixed and heated for reaction, and finally the product is obtained after purification.
In the synthesis method, the catalyst is an iodine reagent selected from the following components: one or more of trimethyl sulfoxide iodide, ammonium iodide, potassium iodide, elemental iodine, iodine chloride, iodobenzene, diethyl iodobenzene, N-iodosuccinimide and diiodo pentoxide; the oxidant is selected from: one or more of dimethyl sulfoxide, methyl phenyl sulfone, methyl benzyl sulfone, TBHP, oxygen, diiodo pentoxide, sodium periodate, potassium persulfate, etc.; the organic solvent is one or more of toluene, xylene, trimethylbenzene, benzotrifluoride, ethylbenzene, chlorobenzene, o-dichlorobenzene, anisole, 1, 4-dioxane, dimethyl sulfoxide, N-methyl pyrrolidone and the like; the mol ratio of the 2- (3-indolyl) cyclohexanone compound to the aniline compound to the catalyst to the oxidant is 1: 0.5-5.0: 0.1-1.0: 0.1 to 10; meanwhile, the reaction temperature is 100-200 ℃.
The synthesis method of the invention is that the general formula of the 2- (3-indolyl) cyclohexanone compound is formula II:
Figure 213518DEST_PATH_IMAGE002
Ⅱ
wherein
R1Selected from hydrogen atoms; a linear, branched alkyl group of C1-C10; a benzyl group; a substituted or unsubstituted C6-C20 aryl group;
R2selected from hydrogen atoms; a linear, branched alkyl group of C1-C10; halogen; an alkoxy group; an ester group; a substituted or unsubstituted C6-C20 aryl group;
R3selected from hydrogen atoms; C1-C10 Linear chain
In the method, the 2- (3-indolyl) cyclohexanone compound in the formula II is selected from 2- (3-indolyl) cyclohexanone; 2- (3- (1-methyl) -indole) cyclohexanone; 2- (3- (1-ethyl) -indole); 2- (3- (1-pentenyl) -indole); 2- (3- (1-isopropyl) -indole); 2- (3- (1-cyclohexyl) -indole); 2- (3- (1-benzyl) -indole); 2- (3- (1, 4 dimethyl) -indole) cyclohexanone; 2- (3- (1, 5 dimethyl) -indole) cyclohexanone; 2- (3- (1, 6 dimethyl) -indole) cyclohexanone; 2- (3- (1, 7 dimethyl) -indole) cyclohexanone; 2- (3- (1-methyl-5 fluoro) -indole) cyclohexanone; 2- (3- (1-methyl-5-bromo) -indole) cyclohexanone; 2- (3- (1-methyl-6-carboxylic acid methyl ester) -indole) cyclohexanone; 2- (3- (1-methyl-6-chloro) -indole) cyclohexanone; 2- (3- (1-methyl) -indole) -2-methylcyclohexanone; 2- (3- (1-methyl) -indole) -4-methylcyclohexanone.
According to the method, the general formula of the aniline compound is shown as a formula III:
Figure 806174DEST_PATH_IMAGE003
Ⅲ
wherein
R4Selected from hydrogen atoms; a linear, branched alkyl group of C1-C10; a carboxyl group; an ester group; an alkoxy group; halogen; a trifluoromethyl group; a substituted or unsubstituted C6-C20 aryl group;
according to the synthesis method, the aniline compound is selected from aniline; 2-methylaniline; 2-phenylaniline; 2-chloroaniline; 3-methylaniline; 3-tert-butylaniline; 3-fluoroaniline; 3-chloroaniline; 3-bromoaniline; 3-trifluoromethylaniline; 3-trifluoromethoxyaniline; 3-nitroaniline; 3-carboxylic acid methyl ester aniline; 3-cyanoaniline; 4-methylaniline, 4-phenylaniline; 4-fluoroaniline; 4-chloroaniline; 4-chloroaniline; 4-bromoaniline; 4-methoxyaniline; 4-trifluoromethoxyaniline; 4-nitroaniline; 4-acetanilide; 3, 3-dibromoaniline, 2-naphthylamine; 2-anthracenamine; 5-amino-2, 2-difluoro-1, 3-benzodioxazole; 1, 3-benzothiazol-5-amine.
The technical scheme of the invention has the following advantages:
the present invention is a compound of indolo [2,3 ]-b]The indole derivatives and the synthesis method thereof do not need to use metal catalysts and metal oxidants, and only under the action of iodine, one or more of toluene, xylene, trimethylbenzene, trifluorotoluene, ethylbenzene, chlorobenzene, o-dichlorobenzene, anisole, 1, 4-dioxane, dimethyl sulfoxide, N-methylpyrrolidone and the like are used as organic reaction solvents to convert 2- (3-indolyl) cyclohexanone, aniline and the derivatives thereof into indolo [2, 3-indolyl ] 2-b]Indole and derivatives thereof; it overcomes the existing indolo [2,3 ]-b]The synthesis method of the indole compound needs to use a metal catalyst,Metal oxidant or the starting raw material with relatively high activity needs to be used; it maintains atom economy to a large extent; it has stable molecular structure, excellent chemical property, molecular blocks and compound fragments containing rich biological activity and pharmacological activity; the method also has the characteristics of simple reaction system, less reaction equipment, simple and convenient operation, cheap and easily obtained raw materials, easy expansion of application, higher product utilization value, expected market commercialization prospect and the like.
The present invention will be described in further detail with reference to the accompanying drawings and examples.
Drawings
In order to demonstrate the products of the invention, the invention provides nuclear magnetic hydrogen and carbon spectra of some of the examples.
FIG. 1-1 nuclear magnetic hydrogen spectrum of the product of example 1.
FIGS. 1-2 nuclear magnetic carbon spectrum of the product of example 1.
FIG. 2-1 nuclear magnetic hydrogen spectrum of the product of example 2.
Figure 2-2 nuclear magnetic carbon spectrum of the product of example 2.
FIG. 3-1 nuclear magnetic hydrogen spectrum of the product of example 3.
Figure 3-2 nuclear magnetic carbon spectrum of the product of example 3.
FIG. 4-1 nuclear magnetic hydrogen spectrum of the product of example 4.
Figure 4-2 nuclear magnetic carbon spectrum of the product of example 4.
FIG. 5-1 nuclear magnetic hydrogen spectrum of the product of example 5.
Figure 5-2 nuclear magnetic carbon spectrum of the product of example 5.
FIG. 6-1 nuclear magnetic hydrogen spectrum of the product of example 6.
Figure 6-2 nuclear magnetic carbon spectrum of the product of example 6.
FIG. 7-1 nuclear magnetic hydrogen spectrum of the product of example 7.
Figure 7-2 nuclear magnetic carbon spectrum of the product of example 7.
FIG. 8-1 nuclear magnetic hydrogen spectrum of the product of example 8.
Figure 8-2 nuclear magnetic carbon spectrum of the product of example 8.
FIG. 9-1 nuclear magnetic hydrogen spectrum of the product of example 9.
Figure 9-2 nuclear magnetic carbon spectrum of the product of example 9.
FIG. 10-1 nuclear magnetic hydrogen spectrum of the product of example 10.
FIG. 10-2 nuclear magnetic carbon spectrum of the product of example 10.
FIG. 11-1 nuclear magnetic hydrogen spectrum of the product of example 11.
FIG. 11-2 nuclear magnetic carbon spectrum of the product of example 11.
FIG. 12-1 nuclear magnetic hydrogen spectrum of the product of example 12.
FIG. 12-2 nuclear magnetic carbon spectrum of the product of example 12.
FIG. 13-1 nuclear magnetic hydrogen spectrum of the product of example 13.
FIG. 13-2 nuclear magnetic carbon spectrum of the product of example 13.
FIG. 14-1 nuclear magnetic hydrogen spectrum of the product of example 14.
FIG. 14-2 nuclear magnetic carbon spectrum of the product of example 14.
FIG. 15-1 nuclear magnetic hydrogen spectrum of the product of example 15.
Figure 15-2 nuclear magnetic carbon spectrum of the product of example 15.
FIG. 16-1 nuclear magnetic hydrogen spectrum of the product of example 16.
Figure 16-2 nuclear magnetic carbon spectrum of the product of example 16.
FIG. 17-1 nuclear magnetic hydrogen spectrum of the product of example 17.
Figure 17-2 nuclear magnetic carbon spectrum of the product of example 17.
FIG. 18-1 nuclear magnetic hydrogen spectrum of the product of example 18.
Figure 18-2 nuclear magnetic carbon spectrum of the product of example 18.
FIG. 19-1 nuclear magnetic hydrogen spectrum of the product of example 19.
Figure 19-2 nuclear magnetic carbon spectrum of the product of example 19.
FIG. 20-1 nuclear magnetic hydrogen spectrum of the product of example 20.
Figure 20-2 nuclear magnetic carbon spectrum of the product of example 20.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to the accompanying drawings, and it should be understood that the described embodiments are some, but not all embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In addition, the technical features involved in the different embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
Indolo [2,3-b ] indoles and derivatives thereof having the general formula:
Figure 372415DEST_PATH_IMAGE004
Ⅰ
wherein the content of the first and second substances,
R1selected from hydrogen atoms; a linear, branched alkyl group of C1-C10; a benzyl group; a substituted or unsubstituted C6-C20 aryl group;
R2selected from hydrogen atoms; a linear, branched alkyl group of C1-C10; halogen; an alkoxy group; an ester group;
R3selected from hydrogen atoms; a linear chain of C1-C10;
R4selected from hydrogen atoms; a linear, branched alkyl group of C1-C10; halogen; an alkoxy group; an ester group; a nitro group; a cyano group; a trifluoromethyl group; a trifluoromethoxy group; acetyl; substituted or unsubstituted C6-C14 aryl
The invention also provides an indolo [2,3 ]-b]The method for preparing indole derivatives is characterized in that a catalyst, an oxidant, aniline compounds, 2- (3-indolyl) cyclohexanone and derivatives thereof and an organic solvent are mixed and heated for reaction, and finally the product is obtained after purification.
In the synthesis method, the catalyst is an iodine reagent selected from the following components: one or more of trimethyl sulfoxide iodide, ammonium iodide, potassium iodide, elemental iodine, iodine chloride, iodobenzene, diethyl iodobenzene, N-iodosuccinimide and diiodo pentoxide; the oxidant is selected from: one or more of dimethyl sulfoxide, methyl phenyl sulfone, methyl benzyl sulfone, TBHP, oxygen, diiodo pentoxide, sodium periodate, potassium persulfate, etc.; the organic solvent is one or more of toluene, xylene, trimethylbenzene, benzotrifluoride, ethylbenzene, chlorobenzene, o-dichlorobenzene, anisole, 1, 4-dioxane, dimethyl sulfoxide, N-methyl pyrrolidone and the like; the mol ratio of the 2- (3-indolyl) cyclohexanone compound to the aniline compound to the catalyst to the oxidant is 1: 0.5-5.0: 0.1-1.0: 0.1 to 10; meanwhile, the reaction temperature is 100-200 ℃.
The synthesis method of the invention is that the general formula of the 2- (3-indolyl) cyclohexanone compound is formula II:
Figure 50521DEST_PATH_IMAGE005
Ⅱ
wherein
R1Selected from hydrogen atoms; a linear, branched alkyl group of C1-C10; a benzyl group; a substituted or unsubstituted C6-C20 aryl group;
R2selected from hydrogen atoms; a linear, branched alkyl group of C1-C10; halogen; an alkoxy group; an ester group; a substituted or unsubstituted C6-C20 aryl group;
R3selected from hydrogen atoms; a linear chain of C1-C10.
In the method, the 2- (3-indolyl) cyclohexanone compound in the formula II is selected from 2- (3-indolyl) cyclohexanone; 2- (3- (1-methyl) -indole) cyclohexanone; 2- (3- (1-ethyl) -indole); 2- (3- (1-pentenyl) -indole); 2- (3- (1-isopropyl) -indole); 2- (3- (1-cyclohexyl) -indole); 2- (3- (1-benzyl) -indole); 2- (3- (1, 4 dimethyl) -indole) cyclohexanone; 2- (3- (1, 5 dimethyl) -indole) cyclohexanone; 2- (3- (1, 6 dimethyl) -indole) cyclohexanone; 2- (3- (1, 7 dimethyl) -indole) cyclohexanone; 2- (3- (1-methyl-5 fluoro) -indole) cyclohexanone; 2- (3- (1-methyl-5-bromo) -indole) cyclohexanone; 2- (3- (1-methyl-6-carboxylic acid methyl ester) -indole) cyclohexanone; 2- (3- (1-methyl-6-chloro) -indole) cyclohexanone; 2- (3- (1-methyl) -indole) -2-methylcyclohexanone; 2- (3- (1-methyl) -indole) -4-methylcyclohexanone.
According to the method, the general formula of the aniline compound is shown as a formula III:
Figure 344099DEST_PATH_IMAGE006
Ⅲ
wherein
R4Selected from hydrogen atoms; a linear, branched alkyl group of C1-C10; a carboxyl group; an ester group; an alkoxy group; halogen; a trifluoromethyl group; a substituted or unsubstituted C6-C20 aryl group;
according to the synthesis method, the aniline compound is selected from aniline; 2-methylaniline; 2-phenylaniline; 2-chloroaniline; 3-methylaniline; 3-tert-butylaniline; 3-fluoroaniline; 3-chloroaniline; 3-bromoaniline; 3-trifluoromethylaniline; 3-trifluoromethoxyaniline; 3-nitroaniline; 3-carboxylic acid methyl ester aniline; 3-cyanoaniline; 4-methylaniline, 4-phenylaniline; 4-fluoroaniline; 4-chloroaniline; 4-chloroaniline; 4-bromoaniline; 4-methoxyaniline; 4-trifluoromethoxyaniline; 4-nitroaniline; 4-acetanilide; 3, 3-dibromoaniline, 2-naphthylamine; 2-anthracenamine; 5-amino-2, 2-difluoro-1, 3-benzodioxazole; 1, 3-benzothiazol-5-amine.
The indolo [2,3 ] is formed by the formulas I, II and III-b]Indole and derivatives thereof are synthesized into the general formula of the reaction system of the invention, as
Figure 56840DEST_PATH_IMAGE007
The method comprises the following steps:
the preparation method comprises the steps of adding a 2- (3-indolyl) cyclohexanone compound, an aniline compound, an iodine reagent, an oxidant and an organic solvent into a reaction vessel;
heating after fully mixing the reactants;
performing purification after the reaction to obtain a product;
wherein the iodine reagent is one or more of methyl sulfoxide iodide, ammonium iodide, potassium iodide, iodine chloride, iodobenzene, diethyl iodobenzene, N-iodosuccinimide, and diiodo pentoxide, preferably trimethyl sulfoxide iodide; the oxidant is one or more of dimethyl sulfoxide, methyl phenyl sulfone, methyl benzyl sulfone, TBHP, oxygen, diiodo pentaoxide, sodium periodate, potassium persulfate, etc., preferably dimethyl sulfoxide; the organic solvent is a single solvent or a mixed solvent of toluene, xylene, trimethylbenzene, trifluorotoluene, ethylbenzene, chlorobenzene, o-dichlorobenzene, anisole, 1, 4-dioxane, dimethyl sulfoxide, N-methylpyrrolidone and the like, and toluene is preferred; the mol ratio of the 2- (3-indolyl) cyclohexanone compound to the aniline compound to the catalyst to the oxidant is 1: 0.5-5.0: 0.1-1.0: 0.1 to 10, preferably 1: 1.5: 0.2: 5; the temperature T of the reaction is between 100 ℃ and 200 ℃, preferably 140 ℃.
In a word, the compound has the advantages that the reaction raw materials are cheap and easy to obtain, and pretreatment is not needed; the reaction does not need to use a catalyst and a metal oxidant or peroxide; only iodine is used as an accelerant, the reaction is directly synthesized in one pot, and the like; the method solves the problems of high cost and the like caused by the conventional multi-step synthesis method; the reaction condition is mild, and the temperature required by the reaction is greatly lower than the reaction temperature of the previous multi-step synthesis; synthetic series of indolo [2,3 ]-b]The indole compound has quite high potential application value.
Referring to the drawings, examples 1-64 are as follows:
example 15-methyl-6-phenyl-5, 6-indolino [2,3 ]-b]Synthesis of indoles
Figure 512092DEST_PATH_IMAGE009
A reaction tube was charged with 0.04 mmol (8.8 mg) of trimethylsulfoxonium iodide, 0.2 mmol (45.4 mg) of 2- (3- (1-methyl) indole) cyclohexanone, 0.3 mmol (27.3. mu.L) of aniline, 1.0 mmol (71.0. mu.L) of dimethyl sulfoxide and 0.5 mL of toluene, and the mixture was sealed and stirred at 140 ℃ to effect reaction for 16 hours, followed by ordinary treatment to obtain 41.5 mg of a pure product in 70% yield.
Following the procedure of example 1, the present invention synthesized the following compounds:
Figure 693806DEST_PATH_IMAGE010
Figure 525496DEST_PATH_IMAGE011
Figure 92744DEST_PATH_IMAGE012
Figure 718897DEST_PATH_IMAGE013
Figure 637174DEST_PATH_IMAGE014
Figure 272555DEST_PATH_IMAGE015
Figure 428730DEST_PATH_IMAGE016
the following gives the characterization data of the compounds of some examples of the present invention, such as nuclear magnetic spectrum, high resolution mass spectrum, etc.:
the nuclear magnetic and mass spectral data of the product of example 1 are as follows:
1H NMR (400 MHz, CDCl3) δ7.98 (t, J = 6.8 Hz, 2H), 7.67-7.52 (m, 5H), 7.37-7.30 (m, 3H), 7.28 (d, J = 7.8 Hz, 1H), 7.24 (d, J = 7.8 Hz, 1H), 7.17 (d, J = 7.6 Hz, 1H), 3.50 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 145.1, 141.3 140.2, 137.2, 129.9, 128.6, 128.2, 122.4, 121.8, 121.1, 120.3 120.0, 120.0, 118.6, 118.3 110.3 109.3 101.2, 30.8.
the nuclear magnetic and mass spectral data of the product of example 2 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.97 (t, J = 6.8 Hz , 2H), 7.52-7.45 (m, 3H), 7.43 (d, J = 7.4 Hz, 1H), 7.34-7.29 (m, 3H), 7.25-7.22 (m, 1H), 7.14 (t, J = 7.6 Hz, 1H), 6.97 (d, J = 8.2 Hz, 1H), 3.41 (s, 3H), 2.05 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 145.1, 140.8, 140.0, 137.9, 135.8, 131.4, 129.6, 129.5, 127.4, 122.2, 122.0, 120.8, 120.3 119.9, 119.7, 118.5, 118.3 110.3 109.2, 100.6, 29.8, 17.5; HRMS (ESI) m/z: [M+H]+ calcd for C22H19N2 + 311.1543; found 311.1542.
the nuclear magnetic and mass spectral data of the product of example 3 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 7.6 Hz, 2H), 7.72 (d, J = 7.4 Hz, 1H), 7.70-7.64 (m, 1H), 7.58 (d, J = 4.4 Hz, 2H), 7.32-7.26 (m, 2H), 7.23-7.18 (m, 2H), 7.16-7.10 (m, 4H), 7.09-7.03 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 145.0, 141.5, 141.4, 140.0, 137.8, 134.3 131.6, 130.5, 129.7, 128.8, 128.5, 128.1, 127.9, 122.2, 121.8, 120.8, 120.0, 119.9, 119.5, 118.4, 118.2, 110.5, 109.0, 100.9, 29.9; HRMS (ESI) m/z: [M+H]+ calcd for C27H21N2 + 373.1699; found 373.1700.
the nuclear magnetic and mass spectral data of the product of example 4 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.91 (t, J = 7.2 Hz, 2H), 7.64 (d, J = 7.6 Hz, 1H), 7.57 (d, J = 6.8 Hz, 1H), 7.52-7.44 (m, 2H), 7.32-7.27 (m, 2H), 7.26-7.20 (m, 2H), 7.10 (t, J = 7.8 Hz, 1H), 6.96 (d, J = 8.0 Hz, 1H), 3.43 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 144.9, 140.8, 139.9, 134.8, 134.4, 131.2, 130.9, 130.6, 128.2, 122.5, 121.8, 121.3 120.3 120.1, 119.9, 118.7, 118.4, 110.2, 109.2, 101.0, 29.8; HRMS (ESI) m/z: [M+H]+ calcd for C21H16ClN2 +331.0997; found 331.0996.
the nuclear magnetic and mass spectral data of the product of example 5 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.95 (t, J = 7.6 Hz, 2H), 7.49 (t, J = 7.6 Hz, 1H), 7.41-7.33 (m, 4H), 7.30 (t, J = 7.4 Hz, 2H), 7.26-7.21 (m, 2H), 7.15 (t, J = 7.6 Hz, 1H), 3.52 (s, 3H), 2.49 (s, 3H); 13C NMR (100 MHz, CDCl3) δ145.2, 141.3 140.2, 140.0, 137.1, 129.6, 129.4, 128.8, 125.2, 122.4, 121.9, 121.0, 120.3 119.9, 119.9, 118.6, 118.3 110.4, 109.2, 101.1, 30.8, 21.5; HRMS (ESI) m/z: [M+H]+ calcd for C22H19N2 + 311.1543; found 311.1542.
the nuclear magnetic and mass spectral data of the product of example 6 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.96 (t, J = 6.8 Hz, 2H), 7.60-7.52 (m, 3H), 7.44-7.39 (m, 1H), 7.37-7.29 (m, 3H), 7.27-7.23 (m, 2H), 7.16 (t, J = 7.2 Hz, 1H), 3.52 (s, 3H), 1.40 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 153.4, 145.1, 141.2, 140.3 136.9, 129.4, 125.4, 125.3 125.1, 122.3 121.9, 121.0, 120.3 120.0, 119.9, 118.6, 118.3 110.4, 109.2, 101.2, 35.1, 31.4, 30.8; HRMS (ESI) m/z: [M+H]+ calcd for C25H25N2 + 353.2012; found 353.2012.
the nuclear magnetic and mass spectral data of the product of example 7 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.96 (t, J = 7.8 Hz, 2H), 7.58 (q, J = 7.4 Hz 1H), 7.39-7.30 (m, 5H), 7.29 (s, 1H), 7.26 (d, J = 8.4 Hz, 2H), 7.18 (t, J= 7.6 Hz, 1H), 3.54 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 163.2 (d, J = 249.7 Hz), 144.7, 141.0, 140.3, 138.8 (d, J = 9.7 Hz), 131.1 (d, J = 9.2 Hz), 123.9 (d, J = 3.3 Hz), 122.6, 121.8, 121.5, 120.5, 120.3, 120.2 118.7, 118.4 115.8, 115.6 (d, J = 4.0 Hz), 115.4, 109.8 (d, J = 81.0 Hz), 101.7, 31.0; 19F NMR (376 MHz, CDCl3) δ-110.1; HRMS (ESI) m/z: [M+H]+ calcd for C21H16FN2 + 315.1292; found 315.1292.
the nuclear magnetic and mass spectral data of the product of example 8 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.95 (t, J = 8.2 Hz, 2H), 7.60 (s, 1H), 7.57-7.50 (m, 2H), 7.50-7.44 (m, 1H), 7.37-7.29 (m, 3H), 7.28-7.22 (m, 2H), 7.17 (t, J = 7.6, Hz, 1H), 3.53 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 144.7, 141.0, 140.2, 138.5, 135.5, 130.8, 128.8, 128.3 126.3 122.6, 121.7, 121.5, 120.5, 120.3 120.2, 118.7, 118.4, 110.2, 109.4, 101.7, 31.1; HRMS (ESI) m/z: [M+H]+ calcd for C21H16ClN2 + 331.0997; found 311.0996.
the nuclear magnetic and mass spectral data of the product of example 9 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.96 (t, J = 8.2 Hz, 2H), 7.76 (s, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.53-7.46 (m, 2H), 7.36 (d, J = 3.6 Hz, 1H), 7.34-7.28 (m, 2H), 7.25 (t, J = 8.0 Hz, 2H), 7.18 (t, J = 7.6 Hz, 1H), 3.53 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 144.7, 141.0, 140.2, 138.6, 131.6, 131.1, 131.1, 126.7, 123.2, 122.6, 121.7, 121.5, 120.4, 120.3 120.2, 118.7, 118.4, 110.2, 109.4, 101.7, 31.0; HRMS (ESI) m/z: [M+H]+ calcd for C21H16BrN2 + 375.0491; found 375.0492.
the nuclear magnetic and mass spectral data of the product of example 10 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.97 (t, J = 7.0 Hz, 2H), 7.87 (s, 1H), 7.82 (d, J = 7.2 Hz, 1H), 7.78-7.73 (m, 2H), 7.39-7.27 (m, 4H), 7.24-7.16 (m, 2H), 3.50 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 144.4, 140.8, 140.1, 137.9, 132.4 (q, J = 33.2 Hz), 131.1, 130.4, 125.0 (q, J = 3.7 Hz), 124.7 (q, J = 3.7 Hz), 123.1(q, J = 270.9 Hz), 122.6, 121.5, 120.4, 120.2, 120.2, 118.6, 118.4, 109.9, 109.3, 101.8 30.9; 19F NMR (376 MHz, CDCl3) δ-62.6; HRMS (ESI) m/z: [M+H]+ calcd for C22H16F3N2 + 365.1260; found 365.1261.
the nuclear magnetic and mass spectral data of the product of example 11 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.96 (t, J = 7.6 Hz, 2H), 7.65 (t, J = 8.0 Hz, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.48 (s, 1H), 7.41 (d, J = 8.2 Hz, 1H), 7.39-7.33 (m, 2H), 7.33-7.31 (m, 1H), 7.30 (d, J = 4.6 Hz, 1H), 7.26 (t, J =6.8 Hz, 1H), 7.18 (t, J =7.2 Hz, 1H), 3.54 (s, 3H); 13C NMR (100 MHz, CDCl3) δ150.0, 144.6, 140.9, 140.3 138.8, 131.1, 126.3 122.7, 121.7, 121.6, 120.9, 120.7, 120.6 (q, J = 256.7)120.5, 120.4, 120.4, 118.7, 118.5, 110.1, 109.4, 101.9, 31.0; 19F NMR (376 MHz, CDCl3) δ-57.8; HRMS (ESI) m/z: [M+H]+ calcd for C22H16F3N2O+ 381.1209; found 381.1208.
the nuclear magnetic and mass spectral data of the product of example 12 are as follows:
1H NMR (400 MHz, DMSO-d6) δ 8.53 (s, 1H), 8.43 (d, J = 8.2 Hz, 1H), 8.20 (d, J = 9.8 Hz, 1H), 7.96 (t, J = 8.2 Hz, 3H), 7.54 (d, J = 9.0 Hz, 1H), 7.32-7.18 (m, 4H), 7.13 (t, J = 7.2 Hz, 1H), 3.54 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 148.7, 144.2, 140.3 139.8, 137.3 134.4, 131.4, 123.3 122.6, 122.0, 121.4, 120.7, 120.3 120.1, 120.1, 118.2, 118.1, 110.0, 100.7, 31.0; HRMS (ESI) m/z: [M+H]+ calcd for C22H16N3O2 + 342.1237; found 342.1236.
the nuclear magnetic and mass spectral data of the product of example 13 are as follows:
1H NMR (400 MHz, CDCl3) δ 8.26 (s, 1H), 8.22 (d, J = 7.8 Hz, 1H), 7.95 (t, J = 7.2 Hz, 2H), 7.78 (d, J = 8.0 Hz, 1H), 7.70 (t, J = 7.8 Hz, 1H), 7.37-7.28 (m, 3H), 7.24 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 7.9 Hz, 1H), 7.15 (t, J = 7.2 Hz, 1H), 3.97 (s, 3H), 3.51 (s, 3H); 13C NMR (100 MHz, CDCl3) δ166.1, 144.8, 141.1, 140.2, 137.6, 132.3 132.1, 130.0, 129.5, 129.0, 122.6, 121.7, 121.4, 120.4, 120.2, 120.2, 118.7, 118.4, 110.1, 109.3 101.7, 52.6, 31.0; HRMS (ESI) m/z: [M+H]+ calcd for C23H19N2O2 + 355.1441; found 355.1441.
the nuclear magnetic and mass spectral data of the product of example 14 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.93 (t, J = 7.0, 2H), 7.89 (s, 1H), 7.82 (d, J = 8.4 Hz, 2H), 7.78-7.72 (m, 1H), 7.39-7.32 (m, 2H), 7.30 (d, J = 8.2 Hz, 2H), 7.20-7.12 (m, 2H), 3.52 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 144.4, 140.9, 140.2, 138.5, 132.4, 131.9, 131.2, 131.0, 122.8, 121.9, 121.6, 120.7, 120.6, 118.8, 118.6, 117.7, 114.3 109.9, 109.5, 102.2, 31.2; HRMS (ESI) m/z: [M+H]+ calcd for C22H16N3 + 322.1339; found 322.1339.
the nuclear magnetic and mass spectral data of the product of example 15 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.95 (t, J = 7.2 Hz, 2H), 7.47-7.38 (m, 4H), 7.36-7.28 (m, 3H), 7.26-7.18 (m, 2H), 7.14 (t, J = 7.2 Hz, 1H), 3.51 (s, 3H), 2.52 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 145.2, 141.4, 140.2, 138.7, 134.4, 130.5, 128.1, 122.3 121.9, 120.9, 120.2, 119.9, 119.8, 118.5, 118.2, 110.3 109.2, 101.0, 30.7, 21.4; HRMS (ESI) m/z: [M+H]+ calcd for C22H19N2 + 311.1543; found 311.1543.
the nuclear magnetic and mass spectral data of the product of example 16 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.94 (t, J = 6.8, 2H), 7.76 (d, J = 8.2 Hz, 2H), 7.67 (d, J = 7.4 Hz, 2H), 7.56 (d, J = 8.2 Hz, 2H), 7.49 (t, J = 7.6 Hz, 2H), 7.41 (t, J = 7.4 Hz, 1H), 7.34-7.27 (m, 3H), 7.25-7.20 (m, 2H), 7.13 (t, J = 8.2 Hz, 1H), 3.50 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 145.0, 141.4, 141.3 140.2, 140.0, 136.2, 129.1, 128.4, 128.4, 128.0, 127.3 122.5, 121.9, 121.1, 120.3 120.1, 120.0, 118.6, 118.3 110.4, 109.3 101.4, 30.9; HRMS (ESI) m/z: [M+H]+ calcd for C27H21N2 + 373.1699; found 373.1798.
the nuclear magnetic and mass spectral data of the product of example 17 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.91 (t, J = 7.0 Hz, 2H), 7.51-7.45 (m, 2H), 7.31-7.27 (m, 3H), 7.26-7.21 (m, 3H), 7.14-7.08 (m, 2H), 3.44 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 162.4 (d, J = 249.0 Hz), 145.0, 141.4, 140.1, 133.6 (d, J = 3.2 Hz), 130.1 (d, J = 8.7 Hz), 122.4, 121.8, 121.2, 120.4, 120.1, 120.07, 118.6, 118.4, 116.9 (d, J = 22.8 Hz), 110.1 109.1, 101.2, 30.7; 19F NMR (376 MHz, CDCl3) δ-112.1; HRMS (ESI) m/z: [M+H]+ calcd for C21H16FN2 + 315.1292; found 315.1268.
the nuclear magnetic and mass spectral data of the product of example 18 are as follows:
1H NMR (400 MHz, DMSO-d6) δ 7.95 (d, J = 7.2 Hz, 2H), 7.74 (s, 4H), 7.52 (d, J = 6.6 Hz, 1H), 7.28-7.17 (m, 3H), 7.12 (m, 2H), 3.53 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 144.3 140.4, 139.7, 135.2, 133.1, 130.0, 129.8, 121.7, 121.0, 120.8, 120.1, 120.0, 119.9, 118.1, 118.0, 110.0, 109.9, 100.3 30.7; HRMS (ESI) m/z: [M+H]+ calcd for C21H16ClN2 + 331.0997; found 311.0959.
the nuclear magnetic and mass spectral data of the product of example 19 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.92 (t, J = 7.4 Hz, 2H), 7.47 (d, J = 8.8 Hz, 2H), 7.36-7.26 (m, 3H), 7.25-7.19 (m, 1H), 7.15-7.08 (m, 4H), 3.93 (s, 3H), 3.50 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 159.8, 145.4, 141.7, 140.2, 129.7, 122.2, 121.9, 120.9, 120.3 119.9, 119.8, 118.5, 118.2, 115.0, 110.3 109.2, 100.8, 55.8, 30.6; HRMS (ESI) m/z: [M+H]+ calcd for C22H19N2O+ 327.1492; found 327.1487.
the nuclear magnetic and mass spectral data of the product of example 20 are as follows:
1H NMR (400 MHz, CDCl3) δ 7.91 (t, J = 7.2 Hz, 2H), 7.53 (d, J = 8.8 Hz, 2H), 7.40 (d, J = 8.6 Hz, 2H), 7.31-7.28 (m, 2H), 7.27-7.20 (m, 2H), 7.13 (d, J = 6.8 Hz, 2H), 3.44 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 148.9, 144.8, 141.2, 140.2, 135.7, 129.6, 122.5, 122.3 121.7, 121.4, 120.9 (q, J = 256.6)120.3 120.2, 118.7, 118.4, 110.1, 109.4, 101.6, 30.9. 19F NMR (376 MHz, CDCl3) δ-57.8; HRMS (ESI) m/z: [M+H]+ calcd for C22H16F3N2O+ 381.1209; found 381.1172.
it should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.

Claims (7)

1. A synthetic method of indolo [2,3-b ] indole is characterized in that a catalyst, an oxidant, an aniline compound, a 2- (3-indolyl) cyclohexanone compound and an organic solvent are mixed and then heated for reaction, and finally purified to obtain a product;
the product is indolo [2,3-b ] indole and its derivatives, and its general formula is formula I:
Figure FDA0003326119260000011
the general formula of the 2- (3-indolyl) cyclohexanone compound is shown as formula II:
Figure FDA0003326119260000012
the general formula of the aniline compound is shown as a formula III:
Figure FDA0003326119260000013
wherein
R1Selected from hydrogen atoms; linear, branched alkyl groups of C1-C10; a cyclohexyl group; a benzyl group;
R2selected from hydrogen atoms; linear, branched alkyl groups of C1-C10; halogen; an alkoxy group; an ester group;
R3selected from hydrogen atoms; linear alkyl of C1-C10;
R4selected from hydrogen atoms; c1-C10 straight chain alkyl, branched chain alkyl; halogen; an alkoxy group; an ester group; a nitro group; a cyano group; a trifluoromethyl group; a trifluoromethoxy group; acetyl; a phenyl group.
2. The method of claim 1, wherein the catalyst is an iodine reagent selected from the group consisting of: one or more of trimethyl sulfoxide iodide, ammonium iodide, potassium iodide, elementary iodine, iodine chloride, iodobenzene, diethyl iodobenzene, N-iodosuccinimide and diiodo pentoxide.
3. The method of claim 1, wherein the oxidizing agent is selected from the group consisting of: one or more of dimethyl sulfoxide, methyl phenyl sulfone, methyl benzyl sulfone, TBHP, oxygen, diiodo pentoxide, sodium periodate and potassium persulfate.
4. The method according to claim 1, wherein the organic solvent is one or more of toluene, xylene, trimethylbenzene, trifluorotoluene, ethylbenzene, chlorobenzene, o-dichlorobenzene, anisole, 1, 4-dioxane, dimethyl sulfoxide, and N-methylpyrrolidone.
5. The method according to claim 1, wherein the molar ratio of the 2- (3-indolyl) cyclohexanone compound to the aniline compound to the catalyst to the oxidant is 1: 0.5-5.0: 0.1-1.0: 0.1 to 10; meanwhile, the reaction temperature is 100-200 ℃.
6. The method of claim 1, wherein the 2- (3-indolyl) cyclohexanone compound of formula ii is selected from the group consisting of 2- (3-indolyl) cyclohexanone; 2- (3- (1-methyl) -indole) cyclohexanone; 2- (3- (1-ethyl) -indole); 2- (3- (1-pentyl) -indole); 2- (3- (1-isopropyl) -indole); 2- (3- (1-cyclohexyl) -indole); 2- (3- (1-benzyl) -indole); 2- (3- (1, 4 dimethyl) -indole) cyclohexanone; 2- (3- (1, 5 dimethyl) -indole) cyclohexanone; 2- (3- (1, 6 dimethyl) -indole) cyclohexanone; 2- (3- (1, 7 dimethyl) -indole) cyclohexanone; 2- (3- (1-methyl-5 fluoro) -indole) cyclohexanone; 2- (3- (1-methyl-5-bromo) -indole) cyclohexanone; 2- (3- (1-methyl-6-carboxylic acid methyl ester) -indole) cyclohexanone; 2- (3- (1-methyl-6-chloro) -indole) cyclohexanone; 2- (3- (1-methyl) -indole) -2-methylcyclohexanone; 2- (3- (1-methyl) -indole) -4-methylcyclohexanone.
7. The method according to claim 1, wherein the aniline compound is selected from aniline; 2-methylaniline; 2-phenylaniline; 2-chloroaniline; 3-methylaniline; 3-tert-butylaniline; 3-fluoroaniline; 3-chloroaniline; 3-bromoaniline; 3-trifluoromethylaniline; 3-trifluoromethoxyaniline; 3-nitroaniline; 3-carboxylic acid methyl ester aniline; 3-cyanoaniline; 4-methylaniline, 4-phenylaniline; 4-fluoroaniline; 4-chloroaniline; 4-chloroaniline; 4-bromoaniline; 4-methoxyaniline; 4-trifluoromethoxyaniline; 4-nitroaniline; 4-acetanilide.
CN202011293410.1A 2020-11-18 2020-11-18 Indolo [2,3-b ] indole derivative and synthetic method thereof Active CN112592344B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011293410.1A CN112592344B (en) 2020-11-18 2020-11-18 Indolo [2,3-b ] indole derivative and synthetic method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011293410.1A CN112592344B (en) 2020-11-18 2020-11-18 Indolo [2,3-b ] indole derivative and synthetic method thereof

Publications (2)

Publication Number Publication Date
CN112592344A CN112592344A (en) 2021-04-02
CN112592344B true CN112592344B (en) 2021-12-10

Family

ID=75183184

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011293410.1A Active CN112592344B (en) 2020-11-18 2020-11-18 Indolo [2,3-b ] indole derivative and synthetic method thereof

Country Status (1)

Country Link
CN (1) CN112592344B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114539266A (en) * 2022-01-17 2022-05-27 湘潭大学 Maleimidocarbazole compound and synthesis method thereof
CN114349759A (en) * 2022-01-25 2022-04-15 曲阜师范大学 Fused ring 3, 3' -biindole derivative and synthesis method thereof
CN114685517B (en) * 2022-05-05 2023-10-24 武汉天马微电子有限公司 Organic compound containing nitrogen heteroaromatic ring and electroluminescent application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105198888A (en) * 2015-10-01 2015-12-30 湘潭大学 2,3a-disubstituted-3H-pyrazole[1,5-a]indole-4(3aH)-ketone, derivative and synthetic method of 2,3a-disubstituted-3H-pyrazole[1,5-a]indole-4(3aH)-ketone and derivative
WO2016116529A1 (en) * 2015-01-20 2016-07-28 Cynora Gmbh Organic molecules, in particular for use in optoelectronic components
CN110818717A (en) * 2018-08-10 2020-02-21 三星显示有限公司 Organic electroluminescent device and condensed cyclic compound for organic electroluminescent device

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1466906A1 (en) * 1999-03-12 2004-10-13 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic urea and related compounds useful as anti-inflammatory agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016116529A1 (en) * 2015-01-20 2016-07-28 Cynora Gmbh Organic molecules, in particular for use in optoelectronic components
CN105198888A (en) * 2015-10-01 2015-12-30 湘潭大学 2,3a-disubstituted-3H-pyrazole[1,5-a]indole-4(3aH)-ketone, derivative and synthetic method of 2,3a-disubstituted-3H-pyrazole[1,5-a]indole-4(3aH)-ketone and derivative
CN110818717A (en) * 2018-08-10 2020-02-21 三星显示有限公司 Organic electroluminescent device and condensed cyclic compound for organic electroluminescent device

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Regioselective three-component synthesis of 1,2-diarylindoles from cyclohexanones,α-hydroxyketones and anilines under transition-metal-free conditions;Cheng Li et al.;《Chem. Commun.》;20190312;第55卷;第4079-4082页 *
Transition-metal-free access to 7-azaindoles;Dong Wang et al.;《Tetrahedron》;20180612;第74卷;第4100-4110 *
基于环己酮氧化脱氢构建碳-碳与碳-杂键;陈劲进等;《化学进展》;20180520;第30卷(第5期);第564-577页 *

Also Published As

Publication number Publication date
CN112592344A (en) 2021-04-02

Similar Documents

Publication Publication Date Title
CN112592344B (en) Indolo [2,3-b ] indole derivative and synthetic method thereof
CN111217850B (en) Preparation method of silicon-based ester compound, electrolyte containing silicon-based ester compound and secondary battery
CN108409625B (en) Preparation method of 2-pyrrolidone compound
CN109265386B (en) Novel method for synthesizing 3-acylated indole derivative through C-H activation
CN109503547B (en) Process for preparing benzodithiolane derivatives
CN111848473A (en) Aryl alkenyl thioether compound and preparation method thereof
CN111285881B (en) Thieno [3,4-b ] indole derivative and synthetic method thereof
CN107619386B (en) Aromatic ring [ c ] carbazole derivative and synthesis method thereof
CN108084110B (en) 3-aminobenzo [ d ] isothiazole, derivative and synthetic method thereof
CN113880800B (en) Synthetic method of methylsulfonyl substituted thioflavonoid compound
CN114349609B (en) Synthesis method of hexabenzocoronene dimer
CN112266365B (en) Method for introducing phenoxazine/phenothiazine functional group to para position of aniline derivative
CN110407830B (en) Method for synthesizing N-arylphenothiazine compound
CN111517904B (en) Preparation method of sulfonyl acetonitrile compound
CN110872295B (en) Method for synthesizing imidazo [1,2-a ] indole compound
CN111925312B (en) Indolyl-substituted indole-3-ketone and synthesis method thereof
JP3561938B2 (en) Method for producing thiophane derivatives
CN110372722B (en) Method for synthesizing sulfur-nitrogen-containing bis-heterocyclic compound
CN114605273B (en) Method for synthesizing arylaminophenol compound by palladium-catalyzed CO-participated 1, 4-eneyne aromatization reaction
CN115286547B (en) Method for synthesizing aryl benzyl thioether compound
CN108503578B (en) Synthetic method of indeno- [1,2-b ] indole-10 (5H) -ketone compound
CN116768852A (en) Preparation method of benzo [ b ] selenophene derivative
CN115850252A (en) Synthesis method of 2-azolyl-3-alkyl indole compound
CN114835713A (en) Synthesis method of 7-methylpyrazolopyrimidine compound
CN117865999A (en) Preparation method of silicon-based benzazepine-ketone compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant